

## Ultra-rapid cycling in BD

I feel Dr. Goldberg's article addressing ultra-rapid cycling (URC) bipolar disorder (BD) ("Ultra-rapid cycling bipolar disorder: A critical look," CURRENT PSYCHIATRY, December 2011, p. 42-52), fell short in 2 critical regards. First, I believe evidence would have supported much stronger or less ambiguous conclusions. Although URC clearly is an observable symptomatic phenomenon, it's not a valid construct within the BD spectrum, per se. To include it as such would only detract from the homogeneity that has been achieved with the resolution of that group to date, thereby dissipating the usefulness of the group from both a clinical and research standpoint. Even the Bottom Line stated that URC "has not been validated as a distinct clinical entity," but "careful evaluation" is recommended "to differentiate URC from affective lability seen in other conditions," thus implicitly validating using the term as a diagnostic entity.

Second, I am disturbed by the article's absence of adult attention-deficit/ hyperactivity disorder (ADHD), the secondary features of which easily rival BD in accounting for a significant proportion of symptoms commonly attributed to URC, if not the preponderance thereof. Notably, ADHD shares the "trait feature" status the article cites as unique to BD. A commonly cited figure places the prevalence of adult ADHD at 4.4% (using DSM-IV criteria) with 75% to 80% of those patients untreated and undiagnosed.1 Comorbidities of >50% with generalized anxiety disorder, 25% with cyclothymia, 30% with drug abuse, and 34% with alcohol abuse/ dependence have been cited,<sup>2,3</sup> there-



December 2011

fore opportunities for misdiagnoses within this cohort abound.

Furthermore, DSM-5 adult ADHD diagnostic criteria may become less restrictive, and 5 years less stringent regarding age of onset, whereas there's no suggestion of including URC—a point which also might have born mention in the discussion.

As a clinician specializing in adult ADHD, I've diagnosed and treated patients previously misdiagnosed with URC and rapid cycling BD, including patients who had been treated unsuccessfully for 15 to 20 years, and switched many from polytherapy (including mood stabilizers) to psychostimulant monotherapy, with lifechanging results achieved in 1 day and confirmed over months or years of follow-up.

An omission of this sort does a disservice to the field by contributing to the already well-documented tendency of clinical psychiatrists to miss a significant diagnosis.

> Richard Bunt, MD Private Practice Melbourne, FL

#### References

- Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006;163(4):716-723.
- A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. Arch Gen Psychiatry. 1999;56(12):1073-1086.
- Shekim WO, Asarnow RF, Hess E, et al. A clinical and demographic profile of a sample of adults with attention deficit hyperactivity disorder, residual state. Compr Psychiatry. 1990;31(5): 416-425.

# Mood instability in ADHD

Dr. Goldberg makes an important point that not all mood lability indicates bipolar disorder (BD) in "Ultrarapid cycling bipolar disorder: A critical look" (CURRENT PSYCHIATRY, December 2011, p. 42-52).

However, there was 1 significant diagnostic omission. Patients with adult attention-deficit/hyperactivity disorder (ADHD) can present with an unremarkable mental status exam, yet can give a history of abrupt episodes of dyscontrol, often in interpersonal situations. As opposed to children manifesting ADHD, where comorbidity with BD is substantial, adults may primarily display impulsivity rather than hyperactivity or inattention. By ignoring this diagnostic consideration, important pharmacotherapeutic options have been discarded, although cognitive-behavioral therapy and dialectical behavior therapy for "borderline" patients are always relevant. Regardless of diagnostic terms and the fate of DSM-5, our treatment approach serves to strengthen prefrontal cortex inhibitory activity and block limbic system reactivity.

> Robert Barris, MD Attending Psychiatrist Nassau University Medical Center East Meadow, NY

> > ß

Send letters to Comments & Controversies, CURRENT PSYCHIATRY, 7 Century Drive, Suite 302, Parsippany, NJ 07054, letters@currentpsychiatry.com, or visit CurrentPsychiatry.com and click on the "Send Letters" link. All letters are subject to editing for brevity and clarity.

## Dr. Goldberg responds

Drs. Bunt and Barris each raise the clinically and theoretically interesting observation that in patients whose childhood attention-deficit/hyperactivity disorder (ADHD) persists into adulthood, affective instability may be a prominent feature. Consequently, they advise that complaints of frequent mood swings within 1 day should alert clinicians to consider ADHD in their differential diagnosis.

Importantly, emotional dysregulation is not an established criterion for ADHD, although investigators have begun to study impaired emotional processing in adults with ADHD.<sup>1</sup> Because observational research examining emotional dysregulation in adult ADHD is preliminary, I cannot concur with Dr. Bunt's assertion that "an omission of this sort does a disservice to the field."

To the contrary, it would seem premature to counsel practitioners to look for mood instability as a red flag for adult ADHD. In fact, given the nontrivial rates of comorbid mood disorders with ADHD as cited by Dr. Bunt, it's plausible that mood instability co-occurring with ADHD simply may be the epiphenomenon of a psychiatric comorbidity such as borderline personality disorder,<sup>2</sup> a disruptive behavior disorder,<sup>3</sup> or substance abuse.<sup>3</sup>

Moreover, endophenotype studies suggest that emotional lability and ADHD do not cosegregate in families.<sup>3</sup> Further research is needed to determine whether moment-to-moment mood fluctuations are an intrinsic feature of ADHD that is not better accounted for by another accompanying condition.

Dr. Bunt appears to have misconstrued my use of the term "validation" with respect to ultra-rapid cycling (URC) as if I had been referring to validation of URC as a diagnosis—which I never suggested rather than as a putative course modifier or specifier in an otherwise-diagnosed bipolar disorder patient—as was the case when researchers empirically validated rapid cycling (RC) as a bipolar course specifier, leading to its inclusion in DSM-IV.<sup>4</sup> To my knowledge there's no movement to consider URC as a bipolar course specifier in DSM-5, which would be a difficult undertaking in the absence of field trials such as those conducted for bipolar RC.

Drs. Barris, Bunt, and I seem to agree that mood shifts occurring on a daily or more frequent basis constitute a nonpathognomonic phenomenon for which "careful evaluation" is necessary to discern the broader psychopathologic condition and context in which it arises.

> Joseph F. Goldberg, MD Associate Clinical Professor of Psychiatry Mt. Sinai School of Medicine New York, NY

### References

- Herrmann MJ, Biehl SC, Jacob C, et al. Neurobiological and psychophysiological correlates of emotional dysregulation in ADHD patients. Atten Defic Hyperact Disord. 2010;2(4):233-239.
- Philipsen A, Feige B, Hesslinger B, et al. Borderline typical symptoms in adult patients with attention deficit/hyperactivity disorder. Atten Defic Hyperact Disord. 2009;1(1):11-18.
- Sobanski E, Banaschewski T, Asherson P, et al. Emotional lability in children and adolescents with attention deficit/hyperactivity disorder (ADHD): clinical correlates and familial prevalence. J Child Psychol Psychiatry. 2010;51(8):915-923.
- Bauer MS, Calabrese J, Dunner DL, et al. Multisite data reanalysis of the validity of rapid cycling as a course modifier for bipolar disorder in DSM-IV. Am J Psychiatry. 1994;151(4):506-515.





The College of Psychiatric and Neurologic Pharmacists (CPNP) is a professional association of psychiatric and neurologic pharmacists. The CPNP Annual Meeting offers cutting-edge information ideal for the pharmacist, physician, nurse practitioner or other healthcare professional involved in the medication therapy management of psychiatric and/or neurologic patients.

### **MEETING HIGHLIGHTS INCLUDE:**

**Pre-Meeting Workshop:** A 7-hour *MTM Boot Camp* workshop will be offered on Sunday, April 29. Led by **Linda Strand, PharmD, PhD**, this workshop (*Incorporating Comprehensive Medication Management* (*MTM*) *into your Practice*) will emphasize the role of the pharmacist in the new organizational structures of the medical home and accountable care organizations. This workshop will demonstrate the keys to defining your service, recruiting patients, demonstrating your value, and charging for and expanding your services—information of value to all pharmacists.

### Daily Keynote Addresses From:

Nassir Ghaemi, MD, MPH: Making Sense of Antidepressants: An Evidence-Based Approach to the Controversies

Barbara Wells, PharmD, FCCP, BCPP: Leadership Lessons Learned

Roy Perlis, MD, MSc: Finding Common Ground Across the Psychosis Spectrum

Madhukar Trivedi, MD: Personalized Medicine in Depression

Judge Steven Leifman, JD: Mental Illness in the Criminal Justice System: Constructing a Comprehensive and Competent Criminal Justice/Mental Health Treatment System

**Programming:** Registrants have 29 hours of ACPE and CME approved programming to choose from along with an anticipated five industry supported symposia opportunities.

**Research/Networking:** Three hours of the meeting will be dedicated to networking with an anticipated 130+ poster authors during 2 scientific poster sessions. Gain additional networking opportunities by participating in hot topic roundtable discussion groups led by your peers.